These observations may help strategize proactive COVID-19 management: administering IL-6 receptor antagonists to high IL-6 patients to mitigate severe inflammatory conditions or recombinant IL-3 to patients with low IL-3 to improve antiviral defense (27–29, 33). Here, IL3 is linked to COVID-19.